G.CLIPS biotech reposted this
C-Level Co-founder Board Member & Advisor - Biotech / Healthcare & Biopharmaceutical companies
📣 Very proud of this fantastic work by G.CLIPS biotech, Roca Therapeutics, Institute for Research On Cancer and Aging, INSERM, Université Côte d’Azur, Centre Scientifique de Monaco (CSM), Christopher Montemagno, Maeva Dufies and Gilles Pagès teams 👏 A fantastic exemple of how G.CLIPS biotech G.Screen technology change the paradigm of therapeutics targeting membrane proteins - here applied for CXCR2 purification and stabilization in native environments as well as on target pharmacological profiling of RCT001 a promising therapeutic target in renal cell carcinoma developed by Roca Therapeutics a Landmark BioVentures AG venture Congratulations to all ! 👏
Co-founder and CEO of G.CLIPS biotech. Pathology-like membrane protein targets for drug and antibody discovery
Very proud to be part of this incredible work on CXCR2 and its ligand RCT001 as a promising therapeutic target in renal cell carcinoma, by Roca Therapeutics, Institute for Research On Cancer and Aging, INSERM, Université Côte d’Azur, Centre Scientifique de Monaco (CSM), Christopher Montemagno, Maeva Dufies and Gilles Pagès. In this work G.CLIPS biotech used it's G.Screen technology for CXCR2 purification and stabilization in native environments as well as on target pharmacological profiling of benchmark ligands and RCT001. Congratulation to all authors: ARNAUD JACQUEL Charlotte Pandiani Olivia Rastoin @Thomas Schmitt Maxence Bourgoin Héliciane Palenzuela Anne-Laure Rossi Damien Ambrosetti Jérôme Durivault Frederic Luciano Delphine Borchiellini @Julie Le Du @Leticia Christina Pires Gonçalves @Patrick AUBERGER Rachid BENHIDA Lisa Kinget @Benoit Beuselinck Cyril Ronco #renalcellcarcinoma, #cxcr2 #inhibitor #chemokine #Immunotherapiesresistance https://lnkd.in/e-5hMNfD
